Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time
- 21 June 2004
- journal article
- clinical trial
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 20 (1) , 122-128
- https://doi.org/10.1002/jmri.20061
Abstract
Purpose To evaluate variability of a simplified method for measuring semiquantitative DCE‐MRI parameters in patients with cancer and to explore effects of treatment with a putative anti‐angiogenic compound. Materials and Methods A total of 19 patients enrolled on treatment trials with the putative anti‐angiogenic agent SU5416 underwent contrast enhanced examinations, and 11 had a second examination eight weeks post therapy. Contrast media concentration as a function of time was calculated using changes in signal and literature baseline T1 values in normal muscle or liver reference tissue. Semiquantitative DCE‐MRI parameters, including the area under the contrast concentration vs. time curve (AUC), were calculated for regions‐of‐interest in normal liver and muscle, and in tumors. Results The coefficients of variation for pretherapy parameters in normal tissue were 11% to 37%. No significant changes were detected in normal liver over two months of therapy. In tumors and muscle, a significant decrease in the AUC and maximum contrast concentration was observed. Conclusion Variability of semiquantitative DCE‐MRI parameters utilizing a method based on known T1 values in a reference tissue is low enough to detect changes in tumors during therapy. Use of this method as a pharmacodynamic marker should be further investigated. J. Magn. Reson. Imaging 2004;20:122–128.Keywords
This publication has 19 references indexed in Scilit:
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- Functional MRI for anticancer therapy assessmentEuropean Journal Of Cancer, 2002
- New Trial Designs to Assess Antitumor and Antiproliferative Agents in Prostate CancerInvestigational New Drugs, 2002
- Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysisNMR in Biomedicine, 2002
- Dynamic Contrast-enhanced MRI Studies in Oncology with an Emphasis on Quantification, Validation and Human StudiesClinical Radiology, 2001
- Development of Target-Based Antineoplastic AgentsInvestigational New Drugs, 2000
- Applications of Magnetic Resonance in Model Systems: Tumor Biology and PhysiologyNeoplasia, 2000
- MR imaging of tumor microcirculation: Promise for the new milleniumJournal of Magnetic Resonance Imaging, 1999
- Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: Standardized quantities and symbolsJournal of Magnetic Resonance Imaging, 1999
- Multicompartment analysis of gadolinium chelate kinetics: Blood-tissue exchange in mammary tumors as monitored by dynamic MR imagingJournal of Magnetic Resonance Imaging, 1999